国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (8): 584-587.doi: 10.3760/cma.j.issn.1673-422X.2016.08.006

• 论著 • 上一篇    下一篇

hepaCAM与多药耐药蛋白在肾癌中的表达及相互关系 

姜小良, 罗旭, 刘如明   

  1. 563000 遵义医学院附属医院泌尿外科(姜小良、罗旭),医学与生物学研究中心(刘如明)
  • 出版日期:2016-08-08 发布日期:2016-07-05
  • 通讯作者: 罗旭,Email: 14246385@qq.com E-mail:14246385@qq.com

Expression and relationship between hepaCAM protein and multidrug resistance protein in renal carcinoma

Xiaoliang, Luo Xu, Liu Ruming   

  1. Department of Urology, Affiliated Hospital of Zunyi Medical College, Zunyi 563000, China
  • Online:2016-08-08 Published:2016-07-05
  • Contact: Luo Xu, Email: 14246385@qq.com E-mail:14246385@qq.com

摘要: 目的  探讨肝细胞黏附分子(hepaCAM)蛋白与几种多药耐药蛋白在肾癌中的表达及其相互关系。方法  使用免疫组织化学法检测人肾癌组织中不同区域的hepaCAM蛋白、多药耐药相关蛋白(MRP)、P-糖蛋白(P-gp)、肺耐药蛋白(LRP)、拓扑异构酶Ⅱ(TOPOⅡ)的表达并分析其相互关系。结果  在肿瘤的周边区,hepaCAM蛋白与MRP、P-gp、LRP蛋白都呈现阳性表达;而在肿瘤的中心区域,hepaCAM蛋白与P-gp、LRP表达为阴性或弱阳性,而MRP、TOPOⅡ蛋白表达为阳性。与肿瘤周边组比较,MRP、TOPOⅡ在肿瘤中心区表达明显增强(31.23±5.67∶23.89±4.56;45.66±2.34∶5.23±0.66),差异有统计学意义(t=-6.20,P=0.00;t=-100.16,P=0.00),而hepaCAM、P-gp、LRP表达明显减弱(3.21±1.12∶27.25±2.23;2.34±0.33∶51.23±3.45;4.22±1.78∶44.23±1.45),差异有统计学意义(t=60.87,P=0.00;t=90.35,P=0.00;t=107.18,P=0.00)。相关分析结果显示hepaCAM蛋白在肾癌肿瘤中心组织的表达与MRP蛋白表达相关(r=0.94,P=0.01),而与P-gp、LRP、TOPOⅡ蛋白表达无关(r=0.22,P=0.44;r=0.14,P=0.80;r=0.34,P=0.07)。结论  hepaCAM蛋白在肾癌中的表达可能与其耐药相关。

关键词: 肾肿瘤, 细胞黏附分子, 多药耐药相关蛋白质类

Abstract: Objective  To investigate the expression and relationship between hepatocyte cell adhesion molecule (hepaCAM) protein and some multidrug resistance proteins in renal carcinoma tissue. Methods  Expressions of hepaCAM, multidrug resistance associated protein (MRP), P-glycoprotein (P-gp), lung resistance protein (LRP), and topoisomerase Ⅱ (TOPO Ⅱ) protein were detected by immunohistochemistry in different areas of human renal cell carcinoma tissues and their relationships were analyzed. Results  In the peripheral zone of renal tumor, hepaCAM, MRP, P-gp and LRP protein were showed positive expression. In the central region of the renal tumor, the expressions of hepaCAM, P-gp and LRP were negative or weakly positive, while the expressions of MRP and TOPO Ⅱ protein were positive. The expressions of MRP and TOPO Ⅱ protein in the central region of tumor were stronger than those in the peripheral zone of tumor (31.23±5.67 vs. 23.89±4.56; 45.66±2.34 vs. 5.23±0.66), with statistically significant differences (t=-6.20, P=0.00; t=-100.16, P=0.00). While the expressions of other proteins (hepaCAM, P-gp and LRP) in the central region of tumor were weaker than those in the peripheral zone of tumor (3.21±1.12 vs. 27.25±2.23; 2.34±0.33 vs. 51.23±3.45; 4.22±1.78 vs. 44.23±1.45), with statistically significant differences (t=60.87, P=0.00; t=90.35, P=0.00; t=107.18, P=0.00). Correlation analysis showed that the expression of hepaCAM protein in the central region of renal carcinoma was related with the expression of MRP protein (r=0.94, P=0.01), but it was not related with the expressions of P-gp, LRP and TOPO Ⅱ protein (r=0.22, P=0.44; r=0.14, P=0.80; r=0.34, P=0.07). Conclusion  The expression of hepaCAM protein in renal carcinoma may be related to tumor drug-resistance.

Key words: Kidney neoplasms, Cell adhesion molecules, Multidrug resistance-associated proteins